BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20197486)

  • 21. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M; Chang S; Hellriegel ET
    Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women.
    Roman D; Bramson C; Ouellet D; Randinitis E; Gardner M
    J Clin Pharmacol; 2005 Dec; 45(12):1407-12. PubMed ID: 16291716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
    Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
    Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
    De Kam PJ; Luo WL; Wenning L; Ratcliffe L; Sisk CM; Royalty J; Radziszewski W; Wagner JA; Lai E
    Platelets; 2014; 25(7):480-7. PubMed ID: 24206527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers.
    Tarral A; Francheteau P; Guerret M
    Pharmacotherapy; 1997; 17(4):791-5. PubMed ID: 9250559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.
    Zussman BD; Kelly J; Murdoch RD; Clark DJ; Mbchb ; Schubert C; Collie H
    Clin Ther; 2001 Jun; 23(6):921-31. PubMed ID: 11440291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.
    Lai E; Schwartz JI; Dallob A; Jumes P; Liu F; Kraft WK; Royalty J; Chodakewitz JA; McCrary Sisk C; Radziszewski W; Wagner JA
    Platelets; 2010; 21(3):191-8. PubMed ID: 20163197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
    Iqbal M; Khuroo A; Batolar LS; Tandon M; Monif T; Sharma PL
    Clin Ther; 2010 Mar; 32(3):588-96. PubMed ID: 20399995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.
    Smit JW; Oh C; Rengelshausen J; Terlinden R; Ravenstijn PG; Wang SS; Upmalis D; Mangold B
    Pharmacotherapy; 2010 Jan; 30(1):25-34. PubMed ID: 20030470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin?
    Cohen E; Almog S; Staruvin D; Garty M
    Isr Med Assoc J; 2002 Oct; 4(10):772-5. PubMed ID: 12389338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
    Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
    Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.
    Sarich TC; Schützer KM; Wollbratt M; Wall U; Kessler E; Eriksson UG
    J Clin Pharmacol; 2004 Aug; 44(8):935-41. PubMed ID: 15286098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.